Combination of Conservative and Interventional Therapy Strategies for Cholangiocellular Carcinoma
Author Information
Author(s): M. Knüppel, S. Kubicka, A. Vogel, N. P. Malek, M. Schneider, F. Papendorf, T. Greten, J. Wedemeyer, A. Schneider
Primary Institution: Hannover Medical School
Hypothesis
The study aims to compare the effects of various treatment strategies on morbidity and mortality in cholangiocarcinoma patients.
Conclusion
Surgical treatment and chemotherapy combined with PDT or TACE may prolong survival in cholangiocarcinoma patients.
Supporting Evidence
- Median survival for all patients was 15.6 months.
- 50.8% of patients were alive one year after diagnosis.
- Surgical patients survived 17.1 months longer than those without surgery.
- Chemotherapy alone prolonged survival by 9.2 months.
- Combination of chemotherapy and TACE prolonged survival by 9.8 months.
- Combination of chemotherapy and PDT showed a 1.8 months longer survival.
Takeaway
Doctors are trying different treatments for a type of liver cancer called cholangiocarcinoma, and some treatments seem to help people live longer.
Methodology
The study analyzed data from 195 patients treated for malignant bile duct tumors, comparing outcomes based on different treatment strategies.
Potential Biases
Potential biases include selection bias due to the retrospective nature and varying treatment protocols.
Limitations
The study is retrospective and has a small sample size, which may limit the validity of the results.
Participant Demographics
The study included 195 patients, with 84 females (43.1%) and 111 males (56.9%), median age at diagnosis was 58.47 years.
Statistical Information
P-Value
P < .01 for surgical treatment survival comparison; P = .47 for chemotherapy; P = .28 for chemotherapy and PDT; P < .05 for chemotherapy and TACE.
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website